Dermatological Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
J Eur Acad Dermatol Venereol. 2010 Oct;24 Suppl 6:10-4. doi: 10.1111/j.1468-3083.2010.03831.x.
Treatment of severe or recalcitrant plaque psoriasis with traditional systemic therapies may be limited by efficacy or safety/tolerability considerations. The latest information on the pathophysiology of psoriasis and its targeted treatment with biological therapy points to an emerging new treatment paradigm: continuous and earlier systemic therapy. However, few comparative trials of systemic treatments for psoriasis have been conducted. The Active Comparator (CNTO 1275/Enbrel) Psoriasis Trial (ACCEPT) is the first head-to-head superiority study comparing two biological agents (ustekinumab and etanercept) in the treatment of plaque psoriasis. The results show that ustekinumab, given as two injections over a 12-week period, achieves significantly superior clinical improvement compared with etanercept 50 mg twice weekly. The level of response was consistent with previously published data for both drugs, and may have important implications for the management of psoriasis.
对于严重或难治性斑块型银屑病患者，传统的全身治疗可能因疗效或安全性/耐受性考虑而受到限制。银屑病病理生理学及其生物治疗的最新信息表明，一种新兴的治疗模式正在出现：持续和更早的全身治疗。然而，针对银屑病的全身治疗进行的比较试验很少。主动对照（CNTO 1275/Enbrel）银屑病试验（ACCEPT）是首次对头对头比较两种生物制剂（乌司奴单抗和依那西普）治疗斑块型银屑病的优越性研究。结果表明，乌司奴单抗在 12 周内进行两次注射，与每周两次给予依那西普 50mg 相比，可显著改善临床症状。应答水平与两种药物之前发表的数据一致，这可能对银屑病的治疗管理具有重要意义。
